Celiac disease screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Screening with tissue transglutaminase (tTG) IgA test is recommended for symptomatic high risk patients. | Screening with [[tissue transglutaminase]] (tTG) IgA test is recommended for symptomatic high risk patients. | ||
==Screening== | ==Screening== | ||
*Screening in asymptomatic persons is not recommended.<ref name="pmid28350935">{{cite journal |vauthors=Chou R, Bougatsos C, Blazina I, Mackey K, Grusing S, Selph S |title=Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force |journal=JAMA |volume=317 |issue=12 |pages=1258–1268 |year=2017 |pmid=28350935 |doi=10.1001/jama.2016.10395 |url=}}</ref> | *Screening in asymptomatic persons is not recommended.<ref name="pmid28350935">{{cite journal |vauthors=Chou R, Bougatsos C, Blazina I, Mackey K, Grusing S, Selph S |title=Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force |journal=JAMA |volume=317 |issue=12 |pages=1258–1268 |year=2017 |pmid=28350935 |doi=10.1001/jama.2016.10395 |url=}}</ref> | ||
*Screening is recommended for symptomatic and high risk patients with positive family history in first and second degree relatives also in patients with other autoimmune diseases such as, type 1 diabetes mellitus, inflammatory luminal gastrointestinal disorders, Down syndrome, Turner syndrome, IgA deficiency, and IgA nephropathy.<ref name="pmid28350935">{{cite journal |vauthors=Chou R, Bougatsos C, Blazina I, Mackey K, Grusing S, Selph S |title=Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force |journal=JAMA |volume=317 |issue=12 |pages=1258–1268 |year=2017 |pmid=28350935 |doi=10.1001/jama.2016.10395 |url=}}</ref> | *Screening is recommended for symptomatic and high risk patients with positive family history in first and second degree relatives also in patients with other [[autoimmune diseases]] such as, [[Diabetes mellitus type 1|type 1 diabetes mellitus]], inflammatory luminal gastrointestinal disorders, [[Down syndrome]], [[Turner syndrome]], [[IgA deficiency]], and [[IgA nephropathy]].<ref name="pmid28350935">{{cite journal |vauthors=Chou R, Bougatsos C, Blazina I, Mackey K, Grusing S, Selph S |title=Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force |journal=JAMA |volume=317 |issue=12 |pages=1258–1268 |year=2017 |pmid=28350935 |doi=10.1001/jama.2016.10395 |url=}}</ref> | ||
*Screening method for celiac disease is tissue transglutaminase (tTG) IgA test. | *Screening method for celiac disease is tissue transglutaminase (tTG) IgA test. | ||
==References== | ==References== | ||
Revision as of 16:20, 31 March 2017
|
Celiac disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Celiac disease screening On the Web |
|
American Roentgen Ray Society Images of Celiac disease screening |
|
Risk calculators and risk factors for Celiac disease screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]
Overview
Screening with tissue transglutaminase (tTG) IgA test is recommended for symptomatic high risk patients.
Screening
- Screening in asymptomatic persons is not recommended.[1]
- Screening is recommended for symptomatic and high risk patients with positive family history in first and second degree relatives also in patients with other autoimmune diseases such as, type 1 diabetes mellitus, inflammatory luminal gastrointestinal disorders, Down syndrome, Turner syndrome, IgA deficiency, and IgA nephropathy.[1]
- Screening method for celiac disease is tissue transglutaminase (tTG) IgA test.